FLX Bio, Inc. is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio's small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment. Its lead candidate, a best-in-class CCR4 inhibitor, entered Phase 1 studies in December 2017 and has the potential to be used alone or in combination with checkpoint inhibitors to treat a variety of cancers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/21/17 | $60,000,000 | Series C |
Celgene Corporation The Column Group Topspin Partners | undisclosed |
